Why This Connecticut Biotech Could be a $1M Opportunity for Investors Post author:Sam Post published:January 23, 2018 Post category:BioPharma Could Cara be the answer for investors itching to make $1 million? Source: BioSpace You Might Also Like Spark Gets FDA Greenlight for Luxturna, The First Gene Therapy for Eye Disease Approved in the U.S. December 18, 2017 These 3 Biotechs Could Have the Most Exciting Late-Stage Cancer Candidates August 21, 2017 Bay Area's Adamas Pharma Pays Big Bucks to Double HQ January 21, 2018
Spark Gets FDA Greenlight for Luxturna, The First Gene Therapy for Eye Disease Approved in the U.S. December 18, 2017
